3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Cardoso, Fátima; Costa, A.; Senkus, Elżbieta; Aapro, Matti; André, Fabrice; H. Barrios, Carlos; Bergh, Jonas; Bhattacharyya, G.S.; Biganzoli, Laura; João Cardoso, Maria; Carey, L.; Corneliussen-James, D.; Curigliano, Giuseppe; Dièras, Véronique; El Saghir, N.; Eniu, Alexandru; Fallowfield, Lesley; Fenech, D.; A. Francis, Prudence; A. Gelmon, Karen; Gennari, Alessandra; Harbeck, Nadia; A. Hudis, Clifford; Kaufman, Bella; E. Krop, Ian; Mayer, Musa; Meijer, Hanneke; Mertz, Shirley; Ohno, Shinji; Pagani, Olivia; Papadopoulos, Efthymios; A. Peccatori, Fedro; Penault‐Llorca, Frédérique; Piccart, Martine; Pierga, Jean‐Yves; S. Rugo, Hope; D. Shockney, Lillie; W. Sledge, George; M. Swain, Sandra; Thomssen, Christoph; Tutt, Andrew; Vorobiof, Daniel; Xu, Binghe; Norton, Larry; P. Winer, Eric

doi:10.1093/annonc/mdw544

Public

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Published in Annals of Oncology • Oct 11, 2016

Authors:

Fátima Cardoso

A. Costa

Elżbieta Senkus

Abstract

Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years and a 5-year survival of only ∼25% [2–4]. Some more recent series seem to indicate an improvem...

Subject

Medicine

Breast cancer

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!